Mass Tort & MDL Plaintiff Funding in New York

New York applies a three-year limitations period to a product- or toxic-tort-based mass tort claim (CPLR §214). New York's distinctive discovery-rule extension for latent-exposure injuries is directly relevant to most mass torts: under CPLR §214-c, the claim generally accrues within three years of discovering the injury, and if the scientific or medical knowledge needed to identify the cause was not yet available, a claimant who discovers that causal link within five years of discovering the injury gets one additional year from the causation discovery to file — a mechanism written specifically for the kind of latent, science-dependent causation questions that define mass tort litigation. New York has no general statute of repose for consumer products.

New York applies pure comparative negligence (CPLR §1411) to a mass tort sounding in strict liability, consistent with the state's adoption of strict products liability in Codling v. Paglia, 32 N.Y.2d 330 (1973) — a plaintiff's own fault reduces recovery proportionally but never bars it outright, which as in California tends to be built into a settlement matrix's graduated point ranges rather than an all-or-nothing litigated defense.

New York has no general statutory cap on compensatory damages in a mass tort action.

Pre-judgment interest is generally unavailable on damages for personal injury caused by negligence in New York prior to verdict (CPLR §5001(b)); a claim resolved through a global settlement matrix instead receives an allocated award rather than a judgment carrying statutory interest.

A New York mass tort claim filed in or removable to federal court can be transferred to a federal MDL under 28 U.S.C. §1407 for coordinated pretrial proceedings. New York also has its own mechanisms for coordinating related state-court cases: a statewide Litigation Coordination Panel can consolidate related actions pending in different New York counties, and New York is home to one of the most prominent state-level coordinated mass tort dockets in the country — NYCAL, the New York County Asbestos Litigation coordinated part of the New York Supreme Court, which has handled a large share of the nation's asbestos litigation for decades.

New York regulates consumer litigation funding under the Consumer Litigation Funding Act (Article 39-H), N.Y. Gen. Bus. Law §§ 899-ccc–899-mmm. Charges to the consumer litigation funding company are capped at 25% of the gross amount recovered on the claim — disclosed verbatim, in 12-pt bold, in the funding contract.

Why is CPLR §214-c especially important in a mass tort case compared with an ordinary injury claim?

Section 214-c was written specifically for the fact pattern most mass torts present: a latent injury where the causal connection to a product or exposure isn't scientifically established until years after the injury itself, and it can add a full extra year to file once that causation link becomes knowable, on top of the standard three-year period from discovering the injury.

This means a New York mass tort plaintiff's timeliness often depends on tracking two separate discovery dates — when the injury was discovered, and separately when the scientific link to the product became knowable — rather than a single accrual date, which is a more involved timing analysis than most other case types in this catalog require.

What is NYCAL and why does it matter for a New York asbestos-related mass tort claim?

NYCAL — the New York County Asbestos Litigation coordinated part — is one of the most active and longest-running state-court mass tort dockets in the country, consolidating asbestos-related claims filed in New York County before dedicated judges with established case-management protocols.

A claim proceeding through NYCAL benefits from decades of developed causation science, defendant identification, and settlement history specific to that docket, which can make timing and valuation more predictable than in a newer, less-established mass tort proceeding — a distinctly favorable characteristic worth weighing in a funding decision on a New York asbestos-related claim specifically.